Neuraxpharm pursues growth strategy for business in Switzerland
The leading European central nervous system specialty company…
Destiny Pharma appoints Dr Yuri Martina as CMO
Destiny Pharma strengthens Executive Management Team with the appointment of Dr Yuri…
Engimmune Therapeutics raises CHF 15.5 million in seed financing to develop novel T-cell receptor therapeutics
Financing co-led by Pureos Bioventures and Novo Holdings with…
Adcendo Appoints Dominik Mumberg, PhD, as Chief Scientific Officer
Brings in-depth R&D expertise in oncology, including ADCs,…
STORM Therapeutics Awarded Innovate UK Grant to Discover and Develop a Novel Coronavirus Therapy Targeting an RNA-Modifying Enzyme
03 May 2022, Cambridge, UK: STORM Therapeutics, the biotechnology…
Verona Pharma Reports First Quarter 2022 Financial Results and Provides Corporate Update
Phase 3 ENHANCE-2 trial on target to report top-line COPD data…
ISA Pharmaceuticals to Present at Business Conferences in May 2022
Oegstgeest, 27 April 2022 – ISA is pleased to announce that…
Invizius Awarded Second Biomedical Catalyst Grant to Research Peritoneal Dialysis Indication for its H-Guard® Technology
Invizius Limited (“Invizius”), a biotechnology company developing…
Futura Medical Full Year Results for the year ended 31 December 2021
Futura Medical plc (AIM: FUM), a pharmaceutical company developing…
Novo Growth – 2021, A Year in Review
Copenhagen, Denmark, 22 April 2022 – Novo Growth, the growth-stage…
Biocomposites wins two Queen’s Awards for Enterprise in Innovation and International Trade
Innovation award recognises STIMULAN Rapid Cure as the only calcium…
Leading inhalation APIs expert Inke to triple production capacity
To meet the growing global demand for respiratory active pharmaceutical…
ISA Pharmaceuticals announces the start of clinical trial using its novel AMPLIVANT® technology
AMPLIVANT® adjuvant technology has the potential to increase…
Destiny Pharma – Audited results for the year ended 31 December 2021
Brighton, United Kingdom - 12 April 2022 - Destiny Pharma plc…
Biocomposites to present data on STIMULAN® and genex® at ECCMID 2022
Research findings from two studies demonstrate the antimicrobial…
We’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
Optimum Strategic Communications’ specialist team has an in-depth understanding of how to communicate complex science to investors and corporate stakeholders. Optimum helps life science companies on their journey as they grow and has been trusted by hundreds of healthcare clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York
